Palbociclib isethionate (Nanjing Gritpharma)

N/A

Report date: 2025/01/26 17:32:25
NME

Base Information

Drug NamePalbociclib isethionate (Nanjing Gritpharma)
Drug Alias NameGP-51501
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 6 degradersCyclin-dependent kinase 4 degraders
TargetsCyclin-dependent kinase 6Cyclin-dependent kinase 4
Therapy Area/IndicationsMetastatic breast cancer
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesNanjing Gritpharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Gritpharma Co Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancer
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A